Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.
Department of Biology, University of Bari "Aldo Moro", 70125 Bari, Italy.
Cells. 2020 Jan 9;9(1):167. doi: 10.3390/cells9010167.
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.
达雷妥尤单抗（Dara）是首个获批用于治疗多发性骨髓瘤（MM）的人源化抗 CD38 mAb。尽管最近的数据在临床实践和试验中显示出非常有前景的结果，但仍有部分患者未获得部分缓解，最终所有患者都出现疾病进展。Dara 通过抗体依赖的细胞介导的细胞毒性（ADCC）、抗体依赖的细胞吞噬作用（ADCP）、补体依赖的细胞毒性（CDC）和免疫调节作用发挥抗-MM 活性。这些多效性机制的失调可能导致 Dara 耐药的发生。了解这种耐药性可能会改善 MM 患者的治疗管理。
